Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?
Wolfgang Korte1,21Center for Laboratory Medicine, 2Center for Hemostaseology and Hemophilia, St Gallen, SwitzerlandAbstract: Circulating factor XIII (FXIII) consists of two active (A) and two carrier (B) subunits in tetrameric form. Congenital FXIII deficiency is a rare autosomal-recessive trait tha...
Main Author: | Korte W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-07-01
|
Series: | Journal of Blood Medicine |
Online Access: | http://www.dovepress.com/catridecacog-a-breakthrough-in-the-treatment-of-congenital-factor-xiii-a17529 |
Similar Items
-
Use of Catridecacog in a patient with severe Factor XIII deficiency undergoing surgery
by: Gianluca Sottilotta, et al.
Published: (2019-02-01) -
New developments in the management of congenital Factor XIII deficiency
by: Fadoo Z, et al.
Published: (2013-05-01) -
Recombinant factor XIII and congenital factor XIII deficiency: an update from human and animal studies
by: Inbal A
Published: (2013-10-01) -
Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence
by: Lone Hvitfeldt Poulsen, et al.
Published: (2022-02-01) -
New developments in the management of congenital Factor XIII deficiency [Corrigendum]
by: Fadoo Z, et al.
Published: (2013-07-01)